• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Monday, January 18, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Oncotarget: Targeted lymphodepletion with a CD45-directed antibody radioconjugate

Bioengineer by Bioengineer
January 11, 2021
in Health
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

“Here the Oncotarget authors describe the results of preclinical studies with an anti-mouse CD45 antibody 30F11”

IMAGE

Credit: Correspondence to – Dale L. Ludwig – [email protected]

Oncotarget recently published “Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy” which reported that Chimeric antigen receptor T cell therapies, and adoptive cell therapy in general, represent one of the most promising anti-cancer strategies.

In contrast to relatively non-specific chemotherapy-derived lymphodepletion, targeted lymphodepletion with radioimmunotherapy directed to CD45 may be a safer and more effective alternative to target and deplete immune cells. Here the authors describe the results of preclinical studies with an anti-mouse CD45 antibody 30F11, labeled with two different beta-emitters 131Iodine and 177Lutetium, to investigate the effect of anti-CD45 RIT lymphodepletion on immune cell types and on tumor control in a model of adoptive cell therapy.

Treatment of mice with 3.7 MBq 131I-30F11 or 1.48 MBq 177Lu-30F11 safely depleted immune cells such as spleen CD4 and CD8 T Cells, B and NK cells as well as Tregs in OT I tumor model while sparing RBC and platelets and enabled E. G7 tumor control. These results support the application of CD45-targeted RIT lymphodepletion with a non-myeloablative dose of 131I-30F11 or 177Lu-30F11 antibody prior to adoptive cell therapy.

Dr. Dale L. Ludwig from Actinium Pharmaceuticals said, “Chimeric antigen receptor (CAR) T cell therapies, and adoptive cell therapy (ACT) in general, represent one of the most promising anti-cancer strategies.“

It is unclear why some patients respond to treatment with adoptive cell therapies such as CAR-T, and others do not, though the tumor immune microenvironment is a likely contributor to variable effect of cell therapy in both hematologic and solid cancers.

Other cell types that contribute to an immunosuppressive tumor microenvironment that may negatively impact CAR-T efficacy include myeloid derived suppressor cells and tumor-associated macrophages.

The CD45 antigen is found on all nucleated immune cells, with increased expression on mature lymphoid and myeloid lineages, leading to preferential depletion of mature immune cells compared to progenitor hematopoietic cells.

Importantly, immunomodulatory cells such as Tregs and MDSC express CD45 and are targets of lymphodepletion with a CD45-targeting antibody-radionuclide conjugate, potentially resulting in better engraftment, activation and persistence of the exogenously added CAR-T cells in patients.

Here the Oncotarget authors describe the results of preclinical studies with an anti-mouse CD45 antibody 30F11, labeled with two different beta-emitters – 131I and 177Lutetium, to investigate the effect of anti-CD45 RIT lymphodepletion on immune cell types and on tumor control in a model of adoptive cell therapy.

The Ludwig Research Team concluded in their Oncotarget Research Paper, “our data supports CD45 targeted RIT lymphodepletion with a non-myeloablative dose of 131I-30F11 or 177Lu-30F11 prior to adoptive cell therapy.”

###

Sign up for free Altmetric alerts about this article

DOI – https://doi.org/10.18632/oncotarget.27731

Full text – https://www.oncotarget.com/article/27731/text/

Correspondence to – Dale L. Ludwig – [email protected]

Keywords – anti-CD45 targeted lymphodepletion, radioimmunotherapy, adoptive cell therapy, 131Iodine, 177Lutetium

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud – https://soundcloud.com/oncotarget

Facebook – https://www.facebook.com/Oncotarget/

Twitter – https://twitter.com/oncotarget

LinkedIn – https://www.linkedin.com/company/oncotarget

Pinterest – https://www.pinterest.com/oncotarget/

Reddit – https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact

[email protected]

18009220957×105

Media Contact
RYAN JAMES JESSUP
[email protected]

Original Source

https://www.oncotarget.com/news/pr/targeted-lymphodepletion-with-a-cd45-directed-antibody-radioconjugate/

Related Journal Article

http://dx.doi.org/10.18632/oncotarget.27731

Tags: BiologyBreast CancerBusiness/EconomicscancerCarcinogensEducationMedicine/HealthPolicy/EthicsProstate Cancer
Share12Tweet7Share2ShareShareShare1

Related Posts

IMAGE

Lasers & molecular tethers create perfectly patterned platforms for tissue engineering

January 18, 2021
IMAGE

Smart vaccine scheme quick to curb rabies threat in African cities

January 18, 2021

New computational tool reliably differentiates between cancer and normal cells from single-cell RNA-sequencing data

January 18, 2021

Timing is of the essence when treating brain swelling in mice

January 18, 2021
Next Post
IMAGE

Rice 'flashes' new 2D materials

IMAGE

Elusive link between seizures, cell signaling protein ID'd in zebrafish

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    The map of nuclear deformation takes the form of a mountain landscape

    53 shares
    Share 21 Tweet 13
  • Blood pressure drug may be key to increasing lifespan, new study shows

    44 shares
    Share 18 Tweet 11
  • New drug form may help treat osteoporosis, calcium-related disorders

    39 shares
    Share 16 Tweet 10
  • People living with HIV face premature heart disease and barriers to care

    58 shares
    Share 23 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

BiologyMaterialsGeneticsPublic HealthCell BiologyInfectious/Emerging DiseasescancerTechnology/Engineering/Computer ScienceMedicine/HealthClimate ChangeChemistry/Physics/Materials SciencesEcology/Environment

Recent Posts

  • Lasers & molecular tethers create perfectly patterned platforms for tissue engineering
  • Latch, load and release: Elastic motion makes click beetles click, study finds
  • Smart vaccine scheme quick to curb rabies threat in African cities
  • How cells move and don’t get stuck
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In